A decade of progress in juvenile idiopathic athritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry.
Kelly NguyenJulie BarsalouDaniah BasodanMichelle BatthishSusanne M BenselerRoberta A BerardNicholas BlanchetteGilles BoireRoxana BolariaAlessandra BrunsDavid A CabralBonnie CameronSarah CampilloTania CellucciMercedes ChanGaëlle ChédevilleAnne-Laure ChetailleAmieleena ChhabraJulie CouturePaul DanceyJean-Jacques De BruyckerErkan DemirkayaMuhammed DhallaCiarán M DuffyBrian M FeldmanDebbie E FeldmanTommy GerschmanElie HaddadLiane HealeJulie HerringtonKristin HoughtonAdam M HuberAndrea HumanNicole JohnsonRoman JurencakBianca LangMaggie LarchéRonald M LaxerClaire M LeBlancJennifer J Y LeeDeborah M LevyLillian LimLily S H LimNadia LucaTara McGrathTamara McMillanPaivi M MiettunenKimberly A MorishitaHon Yan NgKiem OenJonathan ParkRoss E PettyJean-Philippe Proulx-GauthierSuzanne RamseyJohannes RothAlan M RosenbergEvelyn RozenblyumDax G RumseyHeinrike SchmelingRayfel SchneiderRosie ScuccimarriNatalie J ShiffEarl SilvermanGordon SoonLynn SpiegelElizabeth StringerHerman TamShirley M TseLori TuckerStuart TurveyMarinka TwiltKaren Watanabe DuffyRae S M YeungJaime Guzmannull nullPublished in: Rheumatology (Oxford, England) (2023)
Although baseline disease characteristics were comparable in the 2005-2010 and 2017-2021 cohorts, cDMARD and bDMARD use increased with a concurrent increase in minimally active and inactive disease. Improvements in parent and patient reported outcomes were smaller than improvements in disease activity.